» Authors » Javier Loricera

Javier Loricera

Explore the profile of Javier Loricera including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 55
Citations 765
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
1.
Secada-Gomez C, Loricera J, Martin-Gutierrez A, Lopez-Gutierrez F, Garcia-Alcalde L, Nunez-Sayar M, et al.
Intern Emerg Med . 2025 Mar; PMID: 40038164
Aortitis and periaortitis refer to the inflammation of the aortic wall and the surrounding tissues. Both conditions are associated with various diseases and express nonspecific manifestations. Early diagnosis and treatment...
2.
Martin-Gutierrez A, Loricera J, Aldasoro V, Maiz O, De Miguel E, Galindez-Agirregoikoa E, et al.
Semin Arthritis Rheum . 2025 Feb; 71:152655. PMID: 39965513
No abstract available.
3.
Martin-Gutierrez A, Molina-Collada J, Dominguez-Alvaro M, Melero-Gonzalez R, Fernandez-Fernandez E, Silva-Diaz M, et al.
Rheumatology (Oxford) . 2025 Feb; PMID: 39918980
Objective: To determine the prevalence and predictive factors of cerebrovascular accidents (CVA) in giant cell arteritis (GCA). Methods: ARTESER is a large Spanish multicentre registry including patients with GCA from...
4.
Martin-Gutierrez A, Loricera J, Aldasoro V, Maiz O, De Miguel E, Galindez-Agirregoikoa E, et al.
Semin Arthritis Rheum . 2025 Feb; 71:152640. PMID: 39899915
Objective: Tocilizumab (TCZ) is the only biologic approved in Giant Cell Arteritis (GCA). In clinical trials around a quarter of patients relapse during TCZ treatment. We assess the frequency, features...
5.
Maillet F, Nguyen Y, Espitia O, Perard L, Salvarani C, Riviere E, et al.
Rheumatology (Oxford) . 2025 Feb; PMID: 39898825
Objectives: To describe the characteristics and outcome of patients with the association of large vessel vasculitis (LVV, Takayasu arteritis [TA] or giant cell arteritis [GCA]) and inflammatory bowel disease (IBD)....
6.
Blanco R, Aldasoro V, Maiz O, Melero R, Romero-Yuste S, De Miguel E, et al.
Rheumatology (Oxford) . 2024 Dec; PMID: 39658241
Objective: The spectrum of giant cell arteritis (GCA) includes different vascular phenotypes. Tocilizumab (TCZ) is the only biologic currently approved regardless these phenotypes. We aimed to assess the effectiveness of...
7.
Narvaez J, Dominguez M, Agirregoikoa E, Mendizabal J, Abasolo L, Lluch J, et al.
Rheumatology (Oxford) . 2024 Nov; PMID: 39589919
Objetive: To evaluate the frequency and timing of sustained drug-free remission (SDFR) in patients with giant cell arteritis (GCA) and to identify potential predictive factors of this outcome. Methods: Retrospective...
8.
Estrada P, Dominguez-Alvaro M, Melero-Gonzalez R, De Miguel E, Silva-Diaz M, Valero J, et al.
J Clin Med . 2024 Oct; 13(20). PMID: 39458165
Imaging studies have transformed the diagnosis of large vessel vasculitis (LVV) involvement in giant cell arteritis (GCA). A positron emission tomography/computed tomography (PET/CT) scan with 18-fluorodeoxyglucose (18F-FDG) has emerged as...
9.
Lopez-Maraver M, Serrano-Combarro A, Atienza-Mateo B, Del Val N, Casafont-Sole I, Melero-Gonzalez R, et al.
Semin Arthritis Rheum . 2024 Jul; 68:152517. PMID: 39067148
Background: Evidence on abatacept (ABA) utility for rheumatoid arthritis (RA) - associated interstitial lung disease (ILD) is growing. Clinical trials have shown equivalence in subcutaneous (SC) and intravenous (IV) administration...
10.
Martin-Gutierrez A, Loricera J, Narvaez J, Aldasoro V, Maiz O, Vela P, et al.
Eur J Intern Med . 2024 Jun; 129():78-86. PMID: 38908981
Objective: Aortitis in Giant Cell Arteritis (GCA-aortitis) is a frequent complication that may lead to aneurysms. Tocilizumab (TCZ) was approved in GCA, but the efficacy in GCA-aortitis and aneurysms has...